- BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
- Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
- BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way
Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (
https://ibn.fm/eX4AD).
Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (
https://ibn.fm/6C81O). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at
https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the
InvestorBrandNetwork.